Lacosamide G.L. Pharma Gmbh (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons. This stabilizes the inactive channel state, limiting repetitive firing and neuronal hyper‑excitability that contribute to seizure generation, without affecting the fast inactivation phase.

The appropriate dose of Lacosamide is individualized by the prescribing clinician based on factors such as the patient’s age, weight, renal and hepatic function, and response to therapy. Dosage adjustments are made to achieve optimal seizure control while minimizing side effects.

Safety data for Lacosamide in pregnancy and lactation are limited. The potential risks and benefits should be carefully evaluated by a healthcare professional. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative options and monitoring strategies with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents, and it may have a distinct side‑effect profile, making it a valuable option for patients not fully controlled by other medications.

Lacosamide should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Lacosamide is administered orally, typically in tablet form, and taken with or without food as directed by a healthcare provider. The exact dosing schedule and titration are individualized, and patients should follow the prescribing physician’s instructions closely.

Serious adverse events include cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, suicidal thoughts or behaviors, significant liver enzyme elevations, and rare blood disorders. Patients should be monitored for these signs, and any concerning symptoms should prompt immediate medical evaluation.

Lacosamide is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe cardiac conduction abnormalities, uncontrolled arrhythmias, or those taking strong CYP3A4 inducers that may markedly reduce drug exposure.